What to expect: more detail

How fast is the decline, and does it follow one pattern?

Three trajectories are described in the 2026 UK multidisciplinary recommendations, measured with the MRC Prion Disease Rating Scale. The first is a rapid, roughly linear fall over weeks to months, seen across all disease groups. The second is a rapid fall followed by a long plateau at a stage of severe disability. The third is a gradual decline over several years, mostly in inherited prion disease.

Median survival in sporadic CJD is about four to six months, with the large majority of people dying within a year of symptom onset. The CDC gives a median of four to five months to death and describes dementia as the leading symptom, with early unsteadiness, sudden jerky movements and visual disturbance. Methionine homozygosity at codon 129, older age at onset and male sex are associated with shorter survival. Duration in inherited prion disease ranges from weeks to many years, so family history gives little help in predicting an individual course.

Survival once someone reaches akinetic mutism, the advanced stage of wakeful unresponsiveness, varies widely and unpredictably. Clinically assisted nutrition and hydration may lengthen it, and complications such as aspiration pneumonia may shorten it.

Which symptoms appear, and in what order?

Early presentation is heterogeneous and the disease becomes more uniform as it advances. Myoclonus, the brief involuntary muscle jerking that is a hallmark of sporadic CJD, worsens with progression. Gait ataxia and rising muscle tone are common, with tone most severe at a stage when treating it is unlikely to change disability. Continence needs move from prompting and help with hygiene in the early stages to double incontinence later. Swallowing deteriorates with progressive physical and cognitive change, raising aspiration risk.

Neuropsychiatric symptoms can appear and resolve quickly, which is why the recommendations endorse a period of watch and wait before reaching for medication. True delirium appears to be less common than in Alzheimer disease or dementia with Lewy bodies. Agitation is treated as a sign of unmet need, with pain, constipation, dehydration, noise, light and touch assessed first.

Pain is generally reported as not a problematic symptom in sporadic CJD. The exceptions named are distal pain in the thalamic presentation and dysaesthesia, an unpleasant altered sensation, in acquired and inherited forms.

What does symptom treatment rest on?

Expert consensus and observational data. There are no randomised trials of symptom management in prion disease, and most medication guidance is extrapolated from other dementias. Myoclonus is treated when it interferes with function or care or causes distress, with levetiracetam first line and clonazepam reserved for later stages when someone is no longer walking. Sleep is managed first without drugs, then with melatonin, a sedating antidepressant or a hypnotic, weighed against falls and daytime sedation. Decisions about clinically assisted nutrition and hydration follow a capacity review and a best interests process, and current guidance is that it should not routinely be used in people living with severe dementia unless a reversible comorbidity is present.

Fuller detail on drug choices, doses and the end of life sits in palliative and hospice care.

When should planning start?

At diagnosis, in the view of the 2026 recommendations, because during the time taken to reach a diagnosis the person may already have lost decision-making capacity. Where no family is available, an advocate such as an Independent Mental Capacity Advocate can be appointed in the UK. Early palliative care involvement is encouraged for the same reason.

Where are people cared for, and where do they die?

UK data from the National Prion Monitoring Cohort cited in the recommendations give 28 percent of deaths at home, 28 percent in a hospice, 23 percent in a residential or nursing home and 21 percent in hospital. For comparison the paper gives 12.1 percent of dementia deaths in hospital. The authors read the difference as a marker of complex care needs. Reported practice differs by country: deaths in Japan are predominantly in hospitals including long-term care facilities, most people in Germany die in palliative care institutions, and in the United States about two thirds of patients reached palliative care, often late.

What do families and carers need alongside this?

Caregiving in prion disease is described as placing significant stress on the family carer’s physical and mental health, with disease-specific information, training, mental health support, respite and financial help all named as supports. Stigma is linked to misconceptions carried over from the BSE epidemic, with inaccurate concerns about transmission creating unnecessary fear. There is no evidence that CJD is transmitted from person to person through regular social and clinical contact, and routine handling of blood and cerebrospinal fluid needs only standard precautions.

Advice before and after a death is available from national CJD specialists, with local support from the general practitioner, the palliative care team, hospital bereavement services and third sector organisations.

What remains uncertain?

Prognosis for an individual, the course of any particular inherited variant, and the effect of most symptom treatments. The diagnostic side is better defined: CSF real-time quaking-induced conversion, an assay that amplifies misfolded prion protein, allows confident diagnosis in life, and the 2021 international review recommends performing it in every suspected case where it is available, with PRNP genetic analysis considered in all suspected CJD.

The plain-language version of this page is what to expect. Questions about one person’s likely course belong with the treating team, who hold the examination findings and the test results.